Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-25T14:41:09.602Z Has data issue: false hasContentIssue false

7 - Pharmacological Interventions

from Section 1 - Evidence-based Cognitive Rehabilitation

Published online by Cambridge University Press:  25 June 2018

By
Beth S. Slomine ,
Kimberly Kuchinski  and
Stacy J. Suskauer
Edited by
Gianna Locascio  and
Beth S. Slomine
Gianna Locascio
Affiliation:
NYU Langone Health, New York
Beth S. Slomine
Affiliation:
Kennedy Krieger Institute, Baltimore
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Cognitive Rehabilitation for Pediatric Neurological Disorders , pp. 154 - 168
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Brauner, J. V., Johansen, L. M., Roesbjerg, T., Pagsberg, A. K. Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry. J Clin Psychopharmacol 2016;36(5):500–7.CrossRefGoogle ScholarPubMed
2.Rumore, M. M. Medication repurposing in pediatric patients: Teaching old drugs new tricks. J Pediatr Pharmacol Ther 2016;21(1):36–53.Google Scholar
3.Eapen, B. C., Georgekutty, J., Subbarao, B., Bavishi, S., Cifu, D. X. Disorders of consciousness. Phys Med Rehabil Clin N Am 2017 May;28(2):245–58.Google Scholar
4.Giacino, J. T., Whyte, J., Bagiella, E., Kalmar, K., Childs, N., Khademi, A., et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med 2012 Mar 1;366(9):819–26.Google Scholar
5.McMahon, M. A., Vargus-Adams, J. N., Michaud, L. J., Bean, J. Effects of amantadine in children with impaired consciousness caused by acquired brain injury: A pilot study. Am J Phys Med Rehabil 2009;88(7):525–32.CrossRefGoogle ScholarPubMed
6.Patrick, P. D., Blackman, J. A., Mabry, J. L., Buck, M. L., Gurka, M. J., Conaway, M. R. Dopamine agonist therapy in low-response children following traumatic brain injury. J Child Neurol 2006;21(10):879–85.Google Scholar
7.Ugoya, S. O., Akinyemi, R. O. The place of L-dopa/carbidopa in persistent vegetative state. Clin Neuropharmacol 2010;33(6):279–84.Google Scholar
8.Cossu, G. Therapeutic options to enhance coma arousal after traumatic brain injury: State of the art of current treatments to improve coma recovery. Br J Neurosurg 2014;28(2):187–98.CrossRefGoogle ScholarPubMed
9.Yeh, N., Slomine, B., Suskauer, S. Response to neurostimulant trials in a clinical sample of children with acquired brain injury and disorders of consciousness. Brain Injury 2017;31(6–7):779–780.Google Scholar
10.Meyer, M. J., Megyesi, J., Meythaler, J., Murie-Fernandez, M., Aubut, J. A., Foley, N., et al. Acute management of acquired brain injury. Part II: An evidence-based review of pharmacological interventions. Brain Inj 2010;24(5):706–21.Google Scholar
11.Bogner, J., Barrett, R. S., Hammond, F. M., Horn, S. D., Corrigan, J. D., Rosenthal, J., et al. Predictors of agitated behavior during inpatient rehabilitation for traumatic brain injury. Arch Phys Med Rehabil 2015;96(8 Suppl):S274–81.e4.CrossRefGoogle ScholarPubMed
12.Singh, R., Venkateshwara, G., Nair, K. P., Khan, M., Saad, R. Agitation after traumatic brain injury and predictors of outcome. Brain Inj 2014;28(3):336–40.Google Scholar
13.Plantier, D., Luaute, J., SOFMER group. Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice. Ann Phys Rehabil Med 2016;59(1):42–57.Google Scholar
14.Williamson, D. R., Frenette, A. J., Burry, L., Perreault, M. M., Charbonney, E., Lamontagne, F., et al. Pharmacological interventions for agitation in patients with traumatic brain injury: Protocol for a systematic review and meta-analysis. Syst Rev 2016;5(1):193.Google Scholar
15.Parmelee, D. X., O’Shanick, G. J. Carbamazepine-lithium toxicity in brain-damaged adolescents. Brain Inj 1988;2(4):305–8.Google Scholar
16.Brooke, M. M., Patterson, D. R., Questad, K. A., Cardenas, D., Farrel-Roberts, L. The treatment of agitation during initial hospitalization after traumatic brain injury. Arch Phys Med Rehabil 1992;73(10):917–21.Google ScholarPubMed
17.King, B. H., Wright, D. M., Handen, B. L., Sikich, L., Zimmerman, A. W., McMahon, W., et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001;40(6):658–65.Google Scholar
18.Green, L. B., Hornyak, J, E., Hurvitz, E, A. Amantadine in pediatric patients with traumatic brain injury: A retrospective, case-controlled study. Am J Phys Med Rehabil 2004;83(12):893–7.Google Scholar
19.McGrane, I, R., Loveland, J, G. Pharmacogenetics of cytochrome P450 enzymes in American Indian and Caucasian children admitted to a psychiatric hospital. J Child Adolesc Psychopharmacol 2016;26(4):395–9.CrossRefGoogle ScholarPubMed
20.Attard, A., Ranjith, G., Taylor, D. Delirium and its treatment. CNS Drugs 2008;22(8):631–44.Google Scholar
21.Eisendrath, S. J., Shim, J. J. Management of psychiatric problems in critically ill patients. Am J Med 2006;119(1):22–9.Google Scholar
22.Rao, N., Jellinek, H. M., Woolston, D. C. Agitation in closed head injury: Haloperidol effects on rehabilitation outcome. Arch Phys Med Rehabil 1985;66(1):30–4.Google Scholar
23.Phelps, T. I., Bondi, C. O., Ahmed, R. H., Olugbade, Y. T., Kline, A. E. Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficits. J Neurotrauma 2015;32(8):590–7.CrossRefGoogle ScholarPubMed
24.Scott, L. K., Green, R., McCarthy, P. J., Conrad, S. A. Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article. J Neurosurg Pediatr 2009;3(6):484–7.CrossRefGoogle ScholarPubMed
25.Yap, J. L., Wachtel, L. E., Ahn, E. S., Sanz, J. H., Slomine, B. S., Pidcock, F. S. Treatment of cerebellar cognitive affective syndrome with aripiprazole. J Pediatr Rehabil Med 2012;5(3):233–8.Google Scholar
26.Johnson, A. R., DeMatt, E., Salorio, C. F. Predictors of outcome following acquired brain injury in children. Dev Disabil Res Rev 2009;15(2):124–32.CrossRefGoogle ScholarPubMed
27.Visser, J. C., Rommelse, N. N., Greven, C. U., Buitelaar, J. K. Autism spectrum disorder and attention-deficit/hyperactivity disorder in early childhood: A review of unique and shared characteristics and developmental antecedents. Neurosci Biobehav Rev 2016;65:229–63.Google Scholar
28.Huss, M., Duhan, P., Gandhi, P., Chen, C. W., Spannhuth, C., Kumar, V. Methylphenidate dose optimization for ADHD treatment: Review of safety, efficacy, and clinical necessity. Neuropsychiatr Dis Treat 2017;13:1741–51.Google Scholar
29.The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999;56(12):1073–86.Google Scholar
30.Donfrancesco, R., Calderoni, D., Vitiello, B. Open-label amantadine in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17(5):657–64.Google Scholar
31.Mohammadi, M. R., Kazemi, M. R., Zia, E., Rezazadeh, S. A., Tabrizi, M., Akhondzadeh, S. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. Hum Psychopharmacol 2010;25(7–8):560–5.Google Scholar
32.Ekinci, O., Direk, M. C., Gunes, S., Teke, H., Ekinci, N., Yildirim, F., et al. Short-term efficacy and tolerability of methylphenidate in children with traumatic brain injury and attention problems. Brain Dev 2017;39(4):327–36.CrossRefGoogle ScholarPubMed
33.Zhang, W. T., Wang, Y. F. Efficacy of methylphenidate for the treatment of mental sequelae after traumatic brain injury. Medicine (Baltimore) 2017;96(25):e6960.CrossRefGoogle ScholarPubMed
34.Neurobehavioral Guidelines Working Group, Warden, D. L., Gordon, B., McAllister, T. W., Silver, J. M., Barth, J. T., et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma 2006;23(10):1468–501.Google Scholar
35.Schneider, W. N., Drew-Cates, J., Wong, T. M., Dombovy, M. L. Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: An initial double-blind placebo-controlled study. Brain Inj 1999;13(11):863–72.CrossRefGoogle ScholarPubMed
36.Whyte, J., Vaccaro, M., Grieb-Neff, P., Hart, T., Polansky, M., Coslett, H. B. The effects of bromocriptine on attention deficits after traumatic brain injury: A placebo-controlled pilot study. Am J Phys Med Rehabil 2008;87(2):85–99.CrossRefGoogle ScholarPubMed
37.McDowell, S., Whyte, J., D’Esposito, M. Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain 1998;121 (Pt 6):1155–64.Google Scholar
38.Doyle, R. L., Frazier, J., Spencer, T. J., Geller, D., Biederman, J., Wilens, T. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: A case series. J Atten Disord 2006;9(3):543–9.Google Scholar
39.Handen, B. L., Johnson, C. R., McAuliffe-Bellin, S., Murray, P. J., Hardan, A. Y. Safety and efficacy of donepezil in children and adolescents with autism: Neuropsychological measures. J Child Adolesc Psychopharmacol 2011;21(1):43–50.Google Scholar
40.Zhang, L., Plotkin, R. C., Wang, G., Sandel, M, E., Lee, S. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil 2004;85(7):1050–55.Google Scholar
41.Trovato, M., Slomine, B., Pidcock, F., Christensen, J. The efficacy of donepezil hydrochloride on memory functioning in three adolescents with severe traumatic brain injury. Brain Inj 2006;20(3):339–43.Google Scholar
42.Max, J. E., Keatley, E., Wilde, E. A., Bigler, E. D., Schachar, R. J., Saunders, A. E., et al. Depression in children and adolescents in the first 6 months after traumatic brain injury. Int J Dev Neurosci 2012;30(3):239–45.Google Scholar
43.Vasa, R. A., Gerring, J. P., Grados, M., Slomine, B., Christensen, J. R., Rising, W., et al. Anxiety after severe pediatric closed head injury. J Am Acad Child Adolesc Psychiatry 2002;41(2):148–56.Google Scholar
44.Gerring, J. P., Grados, M. A., Slomine, B., Christensen, J. R., Salorio, C. F., Cole, W. R., et al. Disruptive behaviour disorders and disruptive symptoms after severe paediatric traumatic brain injury. Brain Inj 2009;23(12):944–55.Google Scholar
45.Cole, W. R., Gerring, J. P., Gray, R. M., Vasa, R. A., Salorio, C. F., Grados, M., et al. Prevalence of aggressive behaviour after severe paediatric traumatic brain injury. Brain Inj 2008;22(12):932–9.Google Scholar
46.Vasa, R. A., Suskauer, S. J., Thorn, J. M., Kalb, L., Grados, M. A., Slomine, B. S., et al. Prevalence and predictors of affective liability after paediatric traumatic brain injury. Brain Inj 2015;29(7–8):921–8.CrossRefGoogle Scholar
47.Wagner, S., Muller, C., Helmreich, I., Huss, M., Tadic, A. A meta-analysis of cognitive functions in children and adolescents with major depressive disorder. Eur Child Adolesc Psychiatry 2015;24(1):5–19.CrossRefGoogle ScholarPubMed
48.Southammakosane, C., Schmitz, K. Pediatric Psychopharmacology for Treatment of ADHD, Depression, and Anxiety. Pediatrics 2015;136(2):351–9.Google Scholar
49.Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009 15;(2):CD006117. doi(2):CD006117.Google Scholar
50.Centers for Medicare and Medicaid Services. Antidepressant Medications: Us in Pediatric Patients. 2015; Available at: https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ad-pediatric-factsheet11-14.pdf. (Accessed August 17, 2017.)Google Scholar
51.Andersen, G., Stylsvig, M., Sunde, N. Citalopram treatment of traumatic brain damage in a 6-year-old boy. J Neurotrauma 1999;16(4):341–4.CrossRefGoogle ScholarPubMed
52.Mead, G. E., Hsieh, C. F., Lee, R., Kutlubaev, M., Claxton, A., Hankey, G. J., et al. Selective serotonin reuptake inhibitors for stroke recovery: A systematic review and meta-analysis. Stroke 2013;44(3):844–50.Google Scholar
53.Ashman, T. A., Cantor, J. B., Gordon, W. A., Spielman, L., Flanagan, S., Ginsberg, A., et al. A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury. Arch Phys Med Rehabil 2009;90(5):733–40.Google Scholar
54.Jorge, R. E., Acion, L., Burin, D. I., Robinson, R. G. Sertraline for preventing mood disorders following traumatic brain injury: A randomized clinical trial. JAMA Psychiatry 2016;73(10):1041–47.CrossRefGoogle ScholarPubMed
55.Gagner, C., Landry-Roy, C., Laine, F., Beauchamp, M. H. Sleep–wake disturbances and fatigue after pediatric traumatic brain injury: A systematic review of the literature. J Neurotrauma 2015;32(20):1539–52.Google Scholar
56.Ramtekkar, U. P. DSM-5 changes in attention deficit hyperactivity disorder and autism spectrum disorder: Implications for comorbid sleep issues. Children (Basel) 2017;4(8):10.3390/children4080062.Google Scholar
57.Beebe, D. W. Cognitive, behavioral, and functional consequences of inadequate sleep in children and adolescents. Pediatr Clin North Am 2011;58(3):649–65.Google Scholar
58.Allen, S. L., Howlett, M. D., Coulombe, J. A., Corkum, P. V. ABCs of SLEEPING: A review of the evidence behind pediatric sleep practice recommendations. Sleep Med Rev 2016;29:1–14.CrossRefGoogle ScholarPubMed
59.Larson, E. B., Zollman, F. S. The effect of sleep medications on cognitive recovery from traumatic brain injury. J Head Trauma Rehabil 2010;25(1):61–7.CrossRefGoogle ScholarPubMed
60.Whyte, J., Rajan, R., Rosenbaum, A., Katz, D., Kalmar, K., Seel, R., et al. Zolpidem and restoration of consciousness. Am J Phys Med Rehabil 2014;93(2):101–13.Google Scholar
61.Keegan, L. J., Reed-Berendt, R., Neilly, E., Morrall, M. C., Murdoch-Eaton, D. Effectiveness of melatonin for sleep impairment post paediatric acquired brain injury: Evidence from a systematic review. Dev Neurorehabil 2014;17(5):355–62.Google Scholar
62.Mittur, A. Trazodone: Properties and utility in multiple disorders. Expert Rev Clin Pharmacol 2011;4(2):181–96.Google Scholar
63.Sheng, P., Hou, L., Wang, X., Wang, X., Huang, C., Yu, M., et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One 2013;8(12):e81802.Google Scholar
64.PROVIGIL® (modafinil) Tablets [C-IV]. 2007; Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2007/020717s020s013s018lbl.pdf. (Accessed August 17, 2017.)Google Scholar
65.NUVIGIL™ (armodafinil) Tablets [C-IV]. 2007; Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf. (Accessed August 17, 2017.)Google Scholar
66.Kumar, R. Approved and investigational uses of modafinil: An evidence-based review. Drugs 2008;68(13):1803–1839.Google Scholar
67.Kotagal, S. Treatment of narcolepsy and other organic hypersomnias in children. Paediatr Respir Rev 2018;25:19–24.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×